Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
about
Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteriaModern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibilityCritical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic ImagingQuantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissuesEpirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studiesSurvival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancerUltrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer?Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancerEstrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Personalized chemotherapy selection for breast cancer using gene expression profilesThe predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports.Enrichment of high-grade tumors in breast cancer gene expression studies.Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
P2860
Q35000348-CD7B5061-6EFF-468A-8E16-F0C132511C08Q35184055-7B87E72A-6779-4218-BD95-41B135E158E6Q35574950-7290F3D5-9CA3-4F86-80F1-1D756E05E93FQ35975638-D19C3BA2-19A4-4995-A768-5D3EDF0D7EFAQ36104503-5481313A-648E-4332-8165-8114E043E032Q36444728-54C0B375-08CA-4B93-B453-42BC2AE85F7DQ36613900-157EFD4B-387E-47B7-9E98-97D4C17AC10EQ37156474-277B2963-9F90-45AA-8830-A7B2A176403CQ37324851-50522830-B682-43F2-B4C3-CBDD37A26DADQ37352596-AC65DBC3-F47C-4FA9-9E60-C40EC01118D8Q37385251-4326FED0-8B8F-4988-ABDF-9DDA114BCB90Q37565213-E9B2B26F-B9CB-433D-A3FB-911ED2D5A961Q37679039-2F129103-316B-4999-BD1F-C756796D2C84Q38771946-B7325656-CDDB-4ABC-A588-DE5E634030B5Q38833708-6AC132CB-E31D-43B9-B11A-599BCD35D95CQ39311162-650FB8A7-672A-4ECE-9442-AA907FF08F3FQ40179607-118CB461-974C-46F0-AC25-146C06256C0FQ40361140-53C0D0A4-C4C7-441E-BA44-2C39BE92FD55Q45212093-73AD7680-3412-4988-84B5-69ED111E7EF1Q47168191-16315291-B7BE-44C5-8518-8DBF4E6DC46AQ47190059-D000AB92-B564-4AC0-8DBF-036BEE6316B1Q48047542-301E53AC-03CF-42F5-9008-1D6DF645B2CCQ48371625-D22BFD36-4BD0-4A39-88C1-B15D98EA0F0CQ50892020-EA61B6C3-C0C6-4A32-A7E2-987E6EB13D8BQ51018339-096391C7-E62C-4C2D-87CB-A1E5CE3A6BDBQ53116763-4BAFDB4A-59F6-412A-AB44-66B1BF7D3C56
P2860
Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Neoadjuvant chemotherapy in ER ...... and molecular characteristics.
@en
Neoadjuvant chemotherapy in ER ...... and molecular characteristics.
@nl
type
label
Neoadjuvant chemotherapy in ER ...... and molecular characteristics.
@en
Neoadjuvant chemotherapy in ER ...... and molecular characteristics.
@nl
prefLabel
Neoadjuvant chemotherapy in ER ...... and molecular characteristics.
@en
Neoadjuvant chemotherapy in ER ...... and molecular characteristics.
@nl
P2093
P2860
P1476
Neoadjuvant chemotherapy in ER ...... and molecular characteristics.
@en
P2093
I A M Mandjes
J J de Ronde
J Wesseling
M T F D Vrancken Peeters
P M Nederlof
S Rodenhuis
P2860
P2888
P304
P356
10.1007/S10549-011-1488-0
P407
P577
2011-04-07T00:00:00Z
P6179
1052169362